|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 2 of 15
|
1
|
NAMES OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
GlaxoSmithKline plc
|
||
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
; (a) o
; (b) o
|
||
3
|
SEC USE ONLY
|
||
4
|
SOURCE OF FUNDS
WC
|
||
5
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2(e) o
|
||
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
|
||
NUMBER OF SHARES
|
7
|
SOLE VOTING POWER
-0-
|
|
BENEFICIALLY OWNED BY
|
8
|
SHARED VOTING POWER
15,151,499 shares of Common Stock1 (See Items 5(a) and 5(b))
|
|
EACH REPORTING PERSON
|
9
|
SOLE DISPOSITIVE POWER
-0-
|
|
WITH
|
10
|
SHARED DISPOSITIVE POWER
15,151,499 shares of Common Stock (See Items 5(a) and 5(b))
|
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
15,151,499 shares of Common Stock (See Item 5(a))
|
||
12
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES o
|
||
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
19.01% of the shares of Common Stock (See Item 5(a))
|
||
14
|
TYPE OF REPORTING PERSON
CO
|
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 3 of 15
|
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 4 of 15
|
· |
|
upon the request of holders of at least 50% of the securities covered by the Investors’ Rights Agreement, the right to require the Issuer to register such securities under the Securities Act of 1933, as amended (the “Securities Act”);
|
· |
|
upon the Issuer’s registration under the Securities Act of any of its securities, the right to include shares held by GlaxoSmithKline plc and its affiliates in such registration; and
|
· |
|
upon the Issuer’s eligibility to file a registration statement on Form S-3, the right to request such registration on Form S-3, provided that such registration relates to not less than 10% of the then outstanding shares of stock so eligible, for a total price at least $1,000,000, and not more than twice in any 12-month period.
|
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 5 of 15
|
·
|
|
acquire any of the Issuer’s equity securities;
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 6 of 15
|
·
|
|
make or participate in any solicitation of proxies to vote from any holders of the Issuer’s equity securities;
|
·
|
|
form or participate in a “group” within the meaning of Section 13(d)(3) of the Act with any person not bound by the terms of the Governance Agreement with respect to any voting stock;
|
·
|
|
acquire any of the Issuer’s assets or rights to purchase any of the Issuer’s assets except for assets offered for sale by the Issuer or the acquisition or purchase of the Issuer’s assets pursuant to the Collaboration Agreement between the Issuer and GGL, dated as of November 14, 2002 (“Collaboration Agreement”), or the Strategic Alliance Agreement between the Issuer and GGL, dated as of March 30, 2004 (“Strategic Alliance Agreement”);
|
·
|
|
enter into any arrangement or understanding with others to do any of the actions listed immediately above; and
|
·
|
|
act together with others to offer to the Issuer or any of the Issuer’s stockholders any business combination, restructuring, recapitalization or similar transaction involving the Issuer or otherwise seek together with others to control, change or influence the management, board of directors or the Issuer’s policies or nominate any person as a director who is not nominated by the then incumbent directors, or propose any matter to be voted upon by the Issuer’s stockholders.
|
·
|
|
if the Issuer issues equity securities to a third party (other than pursuant to exercise of options issued as compensation to its directors, officers, employees or consultants), GSK has the right to purchase from the Issuer such number of equity securities that would bring GSK’s percentage ownership of the Issuer’s voting stock to the same level that it was at immediately prior to the issuance of equity securities to the third party at the same price at which the equity securities were sold to the third party;
|
·
|
|
GSK has the right to purchase from the Issuer, on a quarterly basis, equity securities comparable to those that are issued as compensation to the Issuer’s directors, officers, employees or consultants during the preceding quarter pursuant to option exercises or vesting of restricted stock, at the fair market value at the time of GSK’s notification to the Issuer of its intention to purchase such equity securities that would bring GSK’s percentage ownership of the Issuer’s voting stock to the same level that it was at immediately prior to such issuances; and
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 7 of 15
|
·
|
|
upon the conversion or exchange of all or any portion of certain convertible indebtedness or the unsecured convertible subordinated notes issued by the Issuer in January 2008, GSK has the right to purchase from Issuer such number of equity securities that would bring GSK’s percentage ownership of the Issuer’s voting stock to the same level as it was immediately prior to such conversion or exchange at a price per share equal to the greater of (x) the conversion price of the convertible indebtedness or convertible notes, as applicable, or (y) the fair market value per share on the date GSK notifies the Issuer of its intention to purchase such equity securities.
|
·
|
|
the acquisition of securities of another biotechnology or pharmaceutical company that owns the Issuer’s equity securities (provided that those shares will be subject to the provisions of the Governance Agreement on the same basis as GSK’s shares of Class A Common Stock); or
|
·
|
|
the making of an offer to acquire equity securities if (i) a person or group (other than GSK) acquires 20% or more of the Issuer’s voting stock or (ii) the Issuer’s board of directors formally acts to facilitate a change in control of the Issuer (other than with GSK), subject to the following conditions:
|
o
|
that the offer be an offer for 100% of the Issuer’s voting stock;
|
o
|
that the offer include no condition as to financing; and
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 8 of 15
|
o |
that the offer includes a condition that the holders of a majority of the shares of the voting stock not owned by GSK accept the offer by tendering their shares or voting their shares in favor of the offer.
|
·
|
that the offer includes no condition as to financing;
|
·
|
that the offer is approved by a majority of the Issuer’s independent directors;
|
·
|
that the offer includes a condition that the holders of a majority of the shares of the voting stock not owned by GSK accept the offer by tendering their shares in the offer; and
|
·
|
that the shares purchased will be subject to the provisions of the Governance Agreement on the same basis as the shares of GSK's Class A Common Stock.
|
·
|
that the offer occurs on or after September 1, 2012;
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 9 of 15
|
·
|
that the offer includes no conditions to financing;
|
·
|
that the offer is approved by a majority of the Issuer’s independent directors; and
|
·
|
that the offer includes a condition that the holders of a majority of the shares of the Issuer’s voting stock not owned by GSK accept the offer by tendering their shares in the offer.
|
·
|
that the offer occurs before September 1, 2012;
|
·
|
that the offer includes no condition as to financing;
|
·
|
that the offer is approved by a majority of the Issuer’s independent directors;
|
·
|
that the offer includes a condition that the holders of a majority of the shares of the voting stock not owned by GSK accept the offer by tendering their shares in the offer; and
|
·
|
that the offer is for the greater of (i) the fair market value per share on the date immediately preceding the date of the first public announcement of the offer or (ii) $162.75 per share (as adjusted to take into account stock dividends, stock splits, recapitalizations and the like).
|
·
|
effect a change in control of the Issuer; or
|
·
|
issue equity securities to one or more parties (other than in an public offering) that would result in that party or parties holding 20% or more of the voting stock.
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 10 of 15
|
·
|
effect the acquisition by the Issuer of any business or assets that would constitute a substantial portion of the Issuer’s business or assets; or
|
·
|
effect the sale, license or transfer of all or a substantial portion of the Issuer’s business or assets unless GSK has no contractual rights over the business or assets in question pursuant to the Issuer’s Strategic Alliance Agreement with GSK, and such sale, license or transfer occurs in the ordinary course of business.
|
·
|
a number of nominees designated by GSK equal to one-third of the aggregate number of directors comprising the Board at that time;
|
·
|
two of the Issuer’s officers nominated by the nominating committee of the Board; and
|
·
|
the remaining members of the Board will be independent directors.
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 11 of 15
|
·
|
a committee representing the interests of the holders of Common Stock;
|
·
|
a committee of independent directors constituted for the purposes of making any determination that is to be made under the terms of the Governance Agreement or the Issuer’s certificate of incorporation; or
|
·
|
a committee in which membership of a director nominated by GSK would be prohibited by applicable law, regulation or stock exchange or trading system listing requirement.
|
·
|
the Issuer’s acquisition of any business or assets that would constitute a substantial portion of its business or assets;
|
·
|
the sale, lease, license, transfer or other disposal of a substantial portion of its business or assets, tangible or intangible, other than dispositions of assets over which GSK has no contractual rights pursuant to agreements with the Issuer or in the ordinary course of business; or
|
·
|
the repurchase or redemption of any of the Issuer’s equity securities other than (i) redemptions required by the terms of the Issuer’s voting stock, (ii) purchases made at fair market value in connection with any deferred compensation plan that we maintain and (iii) repurchases of unvested or restricted stock at or below cost pursuant to a compensation plan.
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 12 of 15
|
|
(a)
|
The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer;
|
|
(b)
|
An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;
|
|
(c)
|
A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;
|
|
(d)
|
Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;
|
|
(e)
|
Any material change in the present capitalization or dividend policy of the Issuer;
|
|
(f)
|
Any other material change in the Issuer’s business or corporate structure including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by Section 13 of the Investment Company Act of 1940;
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 13 of 15
|
|
(g)
|
Changes in the Issuer’s charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;
|
|
(h)
|
Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;
|
|
(i)
|
A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Act; or
|
|
(j)
|
Any action similar to any of those enumerated above.
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 14 of 15
|
1
|
Common Stock Purchase Agreement, dated November 29, 2010, by and among the Issuer, GGL and GSK, a copy of which is incorporated by reference from Exhibit 10.1 to the Current Report on Form 8-K filed by the Issuer on November 29, 2010.
|
2
|
Amended and Restated Investors' Rights Agreement by and among the Issuer and the parties listed therein, dated as of May 11, 2004, a copy of which is incorporated by reference from Exhibit 10.13 the Form S-1 filed by the Issuer on June 10, 2004.
|
3
|
Amended and Restated Governance Agreement by and among the Issuer, GSK and GlaxoSmithKline plc dated as of June 4, 2004, a copy of which is incorporated by reference from Exhibit 10.14 to Amendment No. 1 to the Form S-1 filed by the Issuer on July 26, 2004.
|
4
|
Second Amendment to Amended and Restated Governance Agreement, dated November 29, 2010, which amends the Amended and Restated Governance Agreement dated June 4, 2004, as previously amended May 11, 2007, by and among the Issuer, GSK and GlaxoSmithKline plc, a copy of which is incorporated by reference from Exhibit 10.2 to the Current Report on Form 8-K filed by the Issuer on November 29, 2010.
|
CUSIP No. 88338T104
|
SCHEDULE 13D
|
Page of 15 of 15
|
GLAXOSMITHKLINE PLC | |
/s/ Victoria A. Whyte
By: Victoria A. Whyte
Title: Deputy Company Secretary
|
|
Name
|
Business Address
|
Principal Occupation or Employment
|
Citizenship
|
Board of Directors
|
|||
Andrew Witty
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Chief Executive Officer
|
British
|
Julian Heslop
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Chief Financial Officer
|
British
|
Dr. Moncef Slaoui
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Executive Director
Chairman Research & Development
|
Belgian
|
Sir Christopher Gent
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
Professor Sir Roy Anderson
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
Dr. Stephanie Burns
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
USA
|
Lawrence Culp
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
USA
|
Sir Crispin Davis
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
Sir Deryck Maughan
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
Dr. Daniel Podolsky
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
USA
|
Mr James Murdoch
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
Tom de Swaan
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
Dutch
|
Sir Robert Wilson
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Company Director
|
British
|
Corporate Executive Team
|
|||
Andrew Witty
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Chief Executive Officer
|
British
|
Julian Heslop
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Chief Financial Officer
|
British
|
Daniel Troy
|
One Franklin Plaza
Philadelphia, PA 19102
|
Senior Vice President & General Counsel
|
USA
|
John Clarke
|
One Franklin Plaza
Philadelphia, PA 19102
|
President Consumer Healthcare
|
New Zealand
|
Marc Dunoyer
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Global Head-Rare Disease Unit
|
French
|
Abbas Hussain
|
150 Beach Road
21-00 Gateway West
189720
Singapore
|
President, Emerging Markets
|
British
|
William Louv
|
One Franklin Plaza
Philadelphia, PA 19102
|
Senior Vice President, Core Business Services &
Chief Information Officer
|
USA
|
Daniel J. Phelan
|
One Franklin Plaza
Philadelphia, PA 19102
|
Chief of Staff
|
USA
|
Claire Thomas
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Senior Vice President,
Human Resources
|
British
|
David Pulman
|
Five Moore Drive
PO Box 13398
Research Triangle Park
North Carolina 27709
|
President,
Global Manufacturing & Supply
|
British
|
Dr. Moncef Slaoui
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Executive Director
Chairman Research & Development
|
Belgian
|
David Redfern
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Chief Strategy Officer
|
British
|
Jean Stéphenne
|
Avenue Pascal 2/6
B-100 Wavre
Belgium
|
Chairman, President and General Manager, Biologicals
|
Belgian
|
Edward Gray
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
President,
Pharmaceuticals Europe
|
British
|
Simon Bicknell
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
Senior Vice President, Company Secretary & Compliance Officer
|
British
|
Deirdre Connolly
|
One Franklin Plaza
Philadelphia, PA 19102
|
President,
Pharmaceuticals, North America
|
USA
|
Patrick Vallance
|
980 Great West Road
Brentford
Middlesex, England
TW8 9GS
|
SVP Medicines Discovery & Development, Drug Discovery
|
British
|